National Agency for Food and Drug Administration and Control (NAFDAC) will today commence clinical trials of malaria vaccine nationwide.

As a result, it has mandated that each pharmaceutical company establish a Pharmacovigilance (PV) surveillance section.

PV will revolutionize things, according to the Director-General, Prof. Mojisola Adeyeye, who spoke over the weekend in Lagos.

In a statement by Resident Media Consultant, Sayo Akintola, yesterday, the DG stressed that the industry must put structures in place to ensure monitoring of products across the supply chain.

She maintained that strategies, goals, and clear-cut objectives to achieving the mission must be conceptualised.
Adeyeye said Marketing Authorisation Holders (MAHs) must, as a matter of importance, train and engage relevant stakeholders on the need for pharmacovigilance and use of relevant platforms for reportage of Adverse Drug Reactions/Adverse Events Following Immunisation (ADR/AEFI) to NAFDAC.